Human uveal melanoma expresses NG2 immunoreactivity

British Journal of Ophthalmology

Volumn 87, Issue 5, 2003, Pages 629-632

  Li, Y ^a   Madigan, M C ^b   Lai, K ^b   Conway, R M ^b   Billson, F A ^b   Crouch, R ^c   Allen, B J ^a  

^a ST GEORGE HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c PRINCE OF WALES HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ENZYME ANTIBODY; EOSIN; HEMATOXYLIN; MELANOMA ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 9 2 27; PARAFFIN; PROTEIN NG2; UNCLASSIFIED DRUG;

ANTIBODY LABELING; ARTICLE; CANCER CELL; CANCER GRADING; CELL TYPE; CHOROID; CHOROID MELANOMA; CILIARY BODY; CONTROLLED STUDY; ENUCLEATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; NERVE FIBER; OPTIC NERVE; PIGMENT EPITHELIUM; PIGMENTATION; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RETINA; STAINING; TISSUE SECTION; UVEA MELANOMA;

ADULT; AGED; AGED, 80 AND OVER; ALKALINE PHOSPHATASE; ANTIBODIES, MONOCLONAL; ANTIGENS; ANTIGENS, NEOPLASM; CHOROID; CHOROID NEOPLASMS; CILIARY BODY; HUMANS; IMMUNOHISTOCHEMISTRY; MELANOMA; MIDDLE AGED; OPTIC NERVE; PIGMENT EPITHELIUM OF EYE; PROTEOGLYCANS; RETINA; UVEAL NEOPLASMS;

EID: 0038408611     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.87.5.629     Document Type: Article

References (32)

1. De Laey JJ. Diagnosis and differential diagnosis of malignant melanoma of the choroid. Bull Soc Beige Ophtalmol 1993;248:6.
2. Shields JA, Shields CL, Shah P, et al. Partial lamellar sclerouvectomy for ciliary body and choroidal tumours. Ophthalmology 1991;98:971-83.
3. Damato BE, Paul J, Foulds WS. Risk factors for residual and recurrent uveal melanoma after trans-scleral local resection. Br J Ophthalmol 1996;80:102-8.
4. Conway RM, Chua WC, Qureshi C, et al. Primary iris melanoma: diagnostic features and outcome of conservative surgical treatment. Br J Ophthalmol 2001;85:848-54.
5. Seddon J, Eagamn KM, Gragoudas ES. Choroidal melanoma: prognosis. In: Ryan SJ ed. Retina. 2nd ed St Louis: Mosby, 1994:742-52.
6. Flaherty LE, Unger JM, Liu PY, et al. Metastatic melanoma from intraocular primary tumours. Am J Clin Oncol 1998;21:568-72.
7. Allen BJ. Targeted alpha therapy: evidence for potential efficacy of alpha-immunoconjugates in the management of micrometastatic cancer. Australasian Radiology 1999;43:480-6.
8. Morgan AC, Galloway DR, Reisfeld RA. Production and characterization of monoclonal antibody to a melanoma specific glycoprotein. Hybridama 1981;1:27-36
9. Bumol TF, Reisfeld RA. Unique glycoprotein-proteoglycan complex defined by monoclonal antibody on human melanoma cells. Proc Natl Acad Sci USA 1982;79:1245-9.
10. Schrappe M, Klier FG, Spiro RC, et al. Correlation of chondroitin sulfate proteoglycan expression on proliferation brain capillary endothelial cells with the malignant phenotype of astroglial cells. Cancer Res 1991;51:4986-93.
11. Schroff RW, Woodhouse CS, Foon KA, et al. Intratumor localization of monoclonal antibody in patients with maligant melanoma treated with antibody to a 250 kilodalton melanoma-associated antigen. J Natl Cancer Inst 1985;74:299-306.
12. Bumol TF, Wang QC, Reisfeld RA, et al. Monoclonal antibody and an antibody-toxin conjugate to a cell surface proteoglycan of melanoma cells suppress in vivo tumor growth. Proc Natl Acad Sci USA 1983;80:529-33.
13. Hwang KM, Fodstad O, Oldham RK, et al. Radiolocalization of xenografted human maligant melanoma by a monoclonal antibody (9.2.27) to a melanoma-associated antigen in nude mice. Cancer Res 1985;45:4150-5.
14. Godal A, Fodstad O, Pihl A. Studies on the melanoma of action of abrin-9.2.27 immunotoxin in human melanoma cell lines. Cancer Res 1987;47:6243-7.
15. Schrappe M, Bumol TF, Apelgren LD, et al. Long-term growth suppression of human glioma xenografts by chemoimmunocojugate of 4-desacetylvinblastine-3-carboxyhydrazide and monoclonal antibody 9.2.27. Cancer Res 1992;52:3838-44.
16. Oldham RK, Foon KA, Morgan AC, et al. Monoclonal antibody therapy of malignant melanoma: in vivo localization in cutaneous metastasis after intravenous administration. J Clin Oncol 1984;2:1235-44.
17. Rizvi SMA, Sakkar S, Goozee G, et al. Radioimmunoconjugates for targeted alpha therapy of malignant melanoma. Melanoma Res 2000;10:281-9.
18. Allen BJ, Rizvi SMA, Tian Z. Preclinical targeted alpha therapy for subcutaneous melanoma. Melanoma Res 2002;8:1-8.
19. Cordell AJ, Falini B, Erber WN, et al. Immunoenzymotic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem 1984;32:219-29.
20. Nishiyarna A, Dahlin KJ, Prince JT, et al. The primary structure of NG2, a novel membrane-spanning proteoglycan. J Cell Biol 1991;114:359-71.
21. Pluschke G, Vanek M, Evans A, et al. Molecular cloning of a human melanoma-associated chondroitin sulfate proteoglycan. Proc Natl Acad Sci USA 1996;93:9710-5.
22. Real FX, Houghton AN, Albino AP, et al. Surface antigens of melanomas and melanocytes defined by mouse monoclonal antibodies: specificity, analysis, and comparison of antigen expression in cultured cells and tissues. Cancer Res 1985;45:4401-11.
23. Leger O, Johnson-Leger C, Jackson E, et al. The chondroitin sulfate proteoglycan NG2 is a tumor specific antigen on the chemically induced rat chondrosarcoma HSN. Int J Cancer 1994;58:700-5.
24. Behm FG, Smith FO, Raimondi SC, et al. Human homologue of the rat chondroitin sulfate proteoglycan, NG2, detected by monoclonal antibody 7.1, identifies childhood acute lymphoblastic leukemias with t(4;11)(q21;q23) or t(11;19)(q23;13) and MLL gene rearragements. Blood 1996;87:1134-9.
25. Butt AM, Duncan A, Hornby MF, et al. Cells expressing the NG2 antigen contact nodes of Ranvier in adult CNS white matter. Glia 1999;26:84-91.
26. Schlingemann RO, Rietveld FJ, Kwaspen F, et al. Differential expression of markers for endothelial cells, pericytes, and basal lamina in the microvasculature of tumors and granulation tissue. Am J Pathol 1991;138:1335-47.
27. Ozerdem U, Grako KA, Dahlin-Huppe K, et al. NG2 proteoglycan is expressed exclusively by mural cells during vascular morphogenesis. Dev Dynamics 2001;222:218-27.
28. Ozerdem U, Monosov E, Stallcup WB. NG2 proteoglycan expression by pericytes in pathological microvasculature. Microvascular Res 2002;63:129-34.
29. Pouly S, Becher B, Blain M, et al. Expression of a homologue of rat NG2 on human microglia. Glia 1999;27:259-68.
30. Burg MA, Grako KA, Stallcup WB. Expression of the NG2 proteoglycan enhances the growth and metastatic properties of melanoma cells. J Cell Physiol 1998;177:299-312.
31. Shawler DL, Bartholomew RM, Smith LM, et al. Human response to multiple injections of murine monoclonal IgG. J Immunol 1985;135:1530-5.
32. Burg MA, Pasqualini R, Arap W, et al. NG2 proteoglycan-binding peptides target tumor neovasculature. Cancer Res 1999;59:2869-74.